Skip to main content
Top
Published in: Reactions Weekly 1/2022

01-07-2022 | Breast Cancer | Case report

Trastuzumab-emtansine

Persistent thrombocytopenia: case report

Published in: Reactions Weekly | Issue 1/2022

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Martinez Pradeda A, et al. SAFETY OF ADJUVANT TRASTUZUMAB EMTANSINA FOR RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER. European Journal of Hospital Pharmacy - Science and Practice 29 (Suppl.): A63-A64 abstr. 4CPS-106, Mar 2022. Available from: URL: http://doi.org/10.1136/ejhpharm-2022-eahp.134 [abstract] Martinez Pradeda A, et al. SAFETY OF ADJUVANT TRASTUZUMAB EMTANSINA FOR RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER. European Journal of Hospital Pharmacy - Science and Practice 29 (Suppl.): A63-A64 abstr. 4CPS-106, Mar 2022. Available from: URL: http://​doi.​org/​10.​1136/​ejhpharm-2022-eahp.​134 [abstract]
Metadata
Title
Trastuzumab-emtansine
Persistent thrombocytopenia: case report
Publication date
01-07-2022
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-19018-y

Other articles of this Issue 1/2022

Reactions Weekly 1/2022 Go to the issue

Case report

Tozinameran

Case report

Baclofen

Case report

Artesunate

Case report

Allopurinol

Case report

Azd-1222